Compare PMTS & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PMTS | FULC |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.4M | 285.4M |
| IPO Year | 2015 | 2019 |
| Metric | PMTS | FULC |
|---|---|---|
| Price | $28.24 | $3.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $27.67 | $16.38 |
| AVG Volume (30 Days) | 112.9K | ★ 1.6M |
| Earning Date | 05-05-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.34 | N/A |
| Revenue | ★ $312,189,000.00 | N/A |
| Revenue This Year | $9.95 | N/A |
| Revenue Next Year | $10.02 | N/A |
| P/E Ratio | $83.46 | ★ N/A |
| Revenue Growth | ★ 12.27 | N/A |
| 52 Week Low | $10.81 | $2.83 |
| 52 Week High | $31.25 | $15.74 |
| Indicator | PMTS | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 60.69 | 51.07 |
| Support Level | $27.00 | $3.44 |
| Resistance Level | $31.25 | $3.96 |
| Average True Range (ATR) | 1.04 | 0.09 |
| MACD | -0.30 | 0.00 |
| Stochastic Oscillator | 55.25 | 48.72 |
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit segment, which principally produce secure debit and credit cards and provide card services for U.S. card-issuing financial institutions, including personalization, instant issuance and other payment solutions such as digital push provisioning for mobile wallets; Prepaid Debit, which provides secure packaging solutions, Prepaid Debit Cards, and other integrated prepaid card services to prepaid program managers in the U.S.; and other: principally corporate expenses. The firm generates key revenue from Debit and Credit segment.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.